I ntracerebral hemorrhage (ICH) is still the deadliest type of stroke, with a case fatality rate at 30 days of approximately 40% and severe disability in most of the survivors. 1 Baseline ICH volume is the variable most strongly associated with an unfavorable outcome, 2 and as many as one-third of patients with ICH experience significant hematoma growth. 3 Because of its frequency and association with poor prognosis, 4 hematoma expansion is an appealing target for acute ICH treatment. 5 Stratification of ICH expansion risk may help target patients with the highest likelihood to benefit from antiexpansion treatment. An association of the computed tomographic angiography (CTA) spot sign has been found with hematoma growth in a range of single-center studies 6, 7 and 1 multicenter study 8 and may improve our ability to stratify the risk for hematoma expansion in clinical practice. However, different criteria for spot sign definition have been reported, with heterogeneity in spot sign density, dimension, morphologic features, and CTA window. To our knowledge, the diagnostic performance of different spot sign definitions has never been directly compared, 9 and only 1 spot sign definition was validated in a multicenter study. 8 In the present study, we investigated whether the CTA spot sign is associated with hematoma growth across a wide range of centers in a large international clinical trial and whether it identifies patients with ICH more likely to benefit from intensive BP reduction. In particular, we tested the hypothesis that intensive BP control would reduce ICH expansion and improve outcome in spot sign-positive patients, whereas those without a spot sign would not benefit from intensive BP reduction. As a secondary analysis, we compared the diagnostic performance of the 2 most commonly used spot sign definitions in the association of hematoma expansion and an unfavorable outcome.
Methods

Participants
The SCORE-IT (Spot Sign Score in Restricting ICH Growth) study was a prospective preplanned analysis of patients enrolled in the Antihypertensive Treatment of Acute Cerebral Hemorrhage II (ATACH-II) randomized clinical trial. 10, 11 In ATACH-II, patients with ICH were randomly assigned to intensive (systolic BP target, <140 mm Hg) vs standard (systolic BP target, <180 mm Hg) BP treatment within 4.5 hours after stroke onset. Demographic and clinical characteristics were collected at enrollment in the clinical trial, as previously described. 11, 12 Patients enrolled in ATACH-II were eligible for SCORE-IT if they underwent a CTA. All aspects of the study were approved by the local institutional review boards of each participating center listed at the end of the article. Written informed consent was obtained from patients or family members.
Image Acquisition and Analysis
Axial non-contrast-enhanced computed tomographic (NCCT) and CTA images were obtained at each participant's institution by using standard local protocols. We retrospectively collected the following CTA acquisition variables:
tube current level (in milliamperes) and tube voltage level (in peak kilovoltage). Baseline and follow-up hematoma volumes at 24 hours were calculated on NCCT images with semiautomated computer-assisted volumetric analysis (AnalyzeDirect medical imaging software, version 11.0; AnalyzeDirect, Inc). First-pass CTA images were independently reviewed by trained readers (A.M. and M.J.J.) for spot sign identification according to the 2 most commonly used spot sign definitions. Disagreements in spot sign readings were adjudicated by consensus under the supervision of a neuroradiologist (J.M.R.). For the purposes of this analysis, definition 1 was validated at Massachusetts General Hospital, Boston, 6 whereas definition 2 was validated in the Prediction of Hematoma Growth and Outcome in Patients With Intracerebral Hemorrhage Using the CT-Angiography Spot Sign (PREDICT) study.
8,13
The diagnostic criteria used in spot sign definition 1 consisted of the presence of at least 1 focus of contrast extravasation in the hematoma, with any size or morphologic feature and density greater than 120 Hounsfield units. Definition 2 included intrahematoma contrast extravasation with a minimum diameter of 1.5 mm in any dimension, with spotlike or serpiginous shape, without any connection with vessels outside the hematoma, without corresponding hyperdensity at NCCT, and with attenuation at least double that of the background hematoma (in Hounsfield units). An illustrative comparison of both diagnostic criteria is shown in the eFigure in the Supplement.
All NCCT and CTA images were carefully reviewed to avoid the inclusion of spot sign mimics such as calcifications (visible on NCCT images) or the presence of connection between the spot sign and vessels outside the hematoma.
14 The primary analysis on the effect of intensive BP control in spot signpositive patients was performed using definition 1, as specified in the SCORE-IT study protocol. 10 As a secondary analysis, CTA spot sign-positive patients according to definition 2 underwent analysis. We had initially planned to include only CTA images obtained at those institutions that routinely perform CTA at admission in patients with ICH. However, during the trial,
Key Points
Question Does the computed tomographic angiography spot sign identify the patients with intracerebral hemorrhage who are most likely to benefit from intensive blood pressure reduction?
Findings In this secondary analysis of 133 patients with intracerebral hemorrhage nested in the Antihypertensive Treatment of Acute Cerebral Hemorrhage II randomized clinical trial, intensive blood pressure treatment did not improve outcomes in patients with a spot sign. The proportion of patients with a spot sign and a 90-day modified Rankin Scale score of 4 or greater was 20 of 27 in the intensive treatment group vs 10 of 20 in the standard treatment group.
Meaning
Our results showed no clinical benefit of intensive blood pressure reduction in patients with intracerebral hemorrhage and a spot sign.
heterogeneity across all sites in CTA performance precluded using this inclusion criterion. The main analysis therefore included all CTA images that were obtained within 8 hours from symptom onset (operationally termed early CTA).
15 As a secondary analysis, we included all CTA images irrespective of time performed. Finally, we performed another analysis stratifying the risk for hematoma expansion with the spot sign score, a validated scoring system that accounts for the number, attenuation, and dimension of spot signs. 6 The spot sign score ranges from 0 to 4 and, as the score increases, the likelihood of hematoma growth increases.
Randomization and Masking
Eligible patients were randomized at a 1:1 ratio via a centralized web-based randomization process to the intensive or standard antihypertensive treatment group. A minimization randomization scheme proposed by Pocock and Simon 16 was used to control for age, baseline Glasgow Coma Scale score, presence of intraventricular hemorrhage, and clinical site. These baseline prognostic factors were identified a priori as those with imbalances that could potentially affect the primary outcome of the trial. Because of the nature of the treatment in this trial in which the infusion of nicardipine hydrochloride was titrated to target systolic BP, the treatment physicians and study b Hematoma volume was measured by a central reader. The rapid assessment of the hematoma volume by the site investigator was used to determine eligibility.
c Hematoma expansion was defined as an increase of 33% or more in the hematoma volume from baseline to 24 hours.
d Defined as the presence of at least 1 focus of contrast extravasation in the hematoma with any size or morphologic feature and density of greater than 120 Hounsfield units.
e Defined as intrahematoma contrast extravasation with a minimum diameter of 1.5 mm in any dimension, with spotlike or serpiginous shape, not connected with vessels outside the hematoma, without corresponding hyperdensity on NCCT, and attenuation at least double that of the background hematoma.
f Scores range from 0 to 6, with 6 indicating death.
personnel could not be blinded to treatment assignment. However, all sites were required to designate an individual who was blinded to treatment assignment and did not participate in the randomization or treatment of patients in the trial to be the blinded assessor of the 30-and 90-day outcomes.
Outcome Measures
The primary outcome of the present analysis was the proportion of spot sign-positive patients who experienced hematoma expansion and had a poor functional outcome at 90 days. Hematoma expansion was defined as absolute volume increase of greater than 33% from the baseline ICH volume. 11 Functional outcome was measured with the modified Rankin Scale (mRS) score, and an unfavorable outcome was defined as an mRS score of 4 or greater (range, 0-6, with higher scores indicating greater disability and 6 indicating death) at 3 months.
Statistical Analysis
Continuous variables with normal distribution were expressed as mean (SD) and with nonnormal distribution as median (range), whereas categorical variables were expressed as count (percentage). Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of the 2 spot sign definitions in predicting ICH expansion and poor longterm outcome are presented. The interrater reliability for the identification of any spot sign was determined using the Cohen κ statistic. The association among BP treatment, ICH expansion, and outcome was investigated with a multivariable logistic regression analysis, stratified by spot sign status, and adjusted for known variables associated with hematoma growth and poor outcome in patients with ICH. 3, 17 Owing to the exploratory nature of this study, P < .05 was considered to be statistically significant, and all the analyses were performed using SAS software (version 9.4; SAS Institute Inc).
Results
The ATACH-II study was terminated early as advised by the monitoring board owing to futility. Of 1000 patients in the ATACH-II trial, 133 (13.3%) underwent a CTA within 8 hours after symptom onset (101 before and 32 after randomization) and were included in the present study (83 
Comparison of Different Spot Sign Definitions
The interrater reliability for the identification of any spot sign was 0.75 (95% CI, 0.69-0.81) for definition 1 and 0.79 (95% CI, 0.73-0.85) for definition 2. The number of spot sign-positive CTAs was significantly higher using definition 1 ( Table 2) , and all the spot sign-positive scans identified with definition 2 were also spot sign positive according to definition 1. The diagnostic performance of the 2 spot sign definitions in predicting ICH expansion and unfavorable outcome is summarized in Table 2 .
Effect of Intensive BP Treatment on ICH Expansion and Outcome Table 3 shows the differences between patients positive and negative for the spot sign, stratified by BP treatment (intensive vs standard BP lowering). The proportion of patients with a spot sign and a 90-day mRS score of 4 or greater was 20 of 27 (74.1%) in the intensive treatment group vs 10 of 20 (50%) in the standard treatment group. As expected, patients with a CTA spot sign had a larger baseline hematoma volume and a higher frequency of expansion. Intensive BP reduction was not associated with a significantly lower rate of hematoma expansion in spot sign-positive patients in univariate analysis (7 of 31 [22.6%] vs 6 of 19 [31.6%]; P = .52). We found no indication of an interactive effect between spot sign status and BP treatment. The univariate analysis was repeated including only CTA obtained before randomization using both spot sign definitions (eTables 1 and 2 in the Supplement). After adjustment for potential confounders in the multivariable regression analysis, intensive BP reduction in spot sign-positive patients was not associated with reduced ICH growth or a better outcome at 3 months ( Table 4) . Similar results were found using spot sign definition 2 (Table 4) . We also obtained the same results when we restricted all the analyses to the subgroup of patients who underwent CTA before randomization (n = 101).
A secondary analysis including all patients with a CTA performed within 36 hours from onset (n = 166) showed the same results. Lowering of systolic BP below 140 mm Hg in patients with a spot sign did not significantly reduce the risk for hematoma expansion (relative risk, 0.68; 95% CI, 0.27-1.72; P = .41) and was not associated with improved long-term functional outcome (relative risk of mRS score, ≥4 at 90 days, 1.16; 95% CI, 0.57-2.36; P = .68).
We found no association between BP treatment and risk for hematoma growth also using a different definition of ICH expansion (relative hematoma growth >33% or absolute hematoma growth >6 mL). Finally, patients with a high spot sign score did not benefit from intensive BP reduction, as shown in eTable 3 in the Supplement.
Discussion
This prospective study of the CTA spot sign in ICH is, to our knowledge, the largest performed in terms of the number of hospitals involved and the largest study investigating the role of the CTA spot sign in selecting patients with ICH for antiexpansion treatment. We found that intensive BP lowering did not significantly reduce the rate of expansion and did not result in reduced mortality or severe disability in patients with a spot sign.
Some possible explanations for our findings include the following: (1) BP reduction does not truly influence hematoma expansion, and therefore a predictor of expansion would not help guide this therapy; (2) BP reduction reduces expansion, but the CTA spot sign is an inadequate tool to identify the patients most likely to benefit; and (3) the CTA spot sign could successfully perform this role, but we were underpowered to detect this effect in our analysis. For the first possibility, major trials have failed to convincingly demonstrate that BP lowering reduces hematoma expansion.
11,18 The differences in actual BP achieved may have been inadequate to detect a true effect, but the process of ICH expansion is complex, and in most patients expansion may not be modifiable by BP reduction. For the second possibility, the suboptimal performance of the CTA spot sign in identifying patients at high risk for hematoma growth in this study may also explain our results. Compared with previous reports using the same diagnostic criteria, both definitions of spot sign showed lower sensitivity, specificity, and accuracy for prediction of ICH growth in our analysis. 8, 19 These discrepancies with previous studies may arise from heterogeneity and lack of standardization in the CTA acquisition protocol. The CTA acquisition variables may indeed influence the diagnostic performance of spot sign in identifying patients who will experience expansion. [20] [21] [22] For the third possibility, we may have had inadequate statistical power to detect an effect of intensive BP reduction in patients at high risk for hematoma growth. All these potential explanations are not mutually exclusive, and the lack of statistical power precluded a thorough evaluation of the first 2 possibilities. Finally, the cohort in this study showed some important differences from the general population with ICH. The patients included in our analysis were younger and had smaller hematomas, and more than half had a normal Glasgow Coma Scale score. Case fatality at 90 days was significantly lower (8.3%) compared with that of real-world studies in patients with ICH (30%-40%), 1,17 leaving little room for outcome improvement with BP management (ceiling effect). In addition, the prevalence of the spot sign in this population was relatively high; using definition 1, we detected at least 1 spot sign in nearly 40% of the patients, whereas the prevalence of this imaging Abbreviations: BP, blood pressure; CTA, computed tomographic angiography; ICH, intracerebral hemorrhage; mRS, modified Rankin Scale; RR, relative risk.
a Adjusted for baseline ICH volume and time from onset to baseline non-contrast-enhanced computed tomography (NCCT). Hematoma expansion was defined as an increase of 33% or more in the hematoma volume from baseline to 24 hours.
b Adjusted for age, baseline ICH volume, admission Glasgow Coma Scale score, and presence of intraventricular hemorrhage.
c Defined as the presence of at least 1 focus of contrast extravasation in the hematoma with any size or morphologic feature and density of greater than 120 Hounsfield units.
d Defined as intrahematoma contrast extravasation with a minimum diameter of 1.5 mm in any dimension, with spotlike or serpiginous shape, not connected with vessels outside the hematoma, without corresponding hyperdensity on NCCT, and attenuation at least double that of the background hematoma. marker in previous studies using the same definition ranged from 17% to 23%. 3, [22] [23] [24] This difference may be owing to the fact that only those presenting within an early time frame (4.5 hours) were eligible for the ATACH-II trial, and the spot sign is more prevalent in early presenters 15,25 despite the small baseline hematoma volume and the lack of oral anticoagulant treatment-associated ICH cases possibly having otherwise minimized spot sign detection. 26 The great heterogeneity in the CTA acquisition protocol may also account for the high rate of spot sign-positive scans. The presence of poor-quality CTA images may indeed have led to the detection of false spot signs. Our findings have important implications for future studies aimed at reducing hematoma growth in patients with ICH. First, if CTA is to be used, a protocol optimized for spot sign detection must be performed, 22 which will likely help with accuracy and specificity. Second, we noted some differences in the diagnostic performance of the 2 spot sign definitions. Definition 1 had a higher sensitivity and therefore may be more suitable for selecting patients for antiexpansion treatments with minimal risk to capture as many patients as possible at high risk for hematoma growth. However, definition 2 appears to show higher specificity and may be preferred in future trials selecting patients for treatment with hemostatic therapies that may be associated with risks such as thrombotic complications. Several NCCT imaging markers have been recently reported as potentially associated with hematoma growth.
Intensive Blood Pressure Reduction and Spot Sign in ICH
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Because of the low cost and wide availability, such NCCT findings may be an option for future studies to stratify the risk for ICH growth and select patients for expansiontargeted treatments.
Limitations
The main limitation of our study is the small proportion of patients who underwent CTA as part of their diagnostic workup. This analysis had an 11% power to detect a 10% difference in the risk for unfavorable outcomes between the two treatment groups at the P < .05 level. The presence of a ceiling effect owing to a mildly affected study population further reduced our power to detect a significant effect of BP treatment on ICH growth and outcome. In addition, the absolute difference in systolic BP in the 2 treatment arms was smaller compared with the expected values based on the suggested cutoffs (140 vs 180 mm Hg). The mean minimum systolic BP at 2 hours was 129 mm Hg in the intensive treatment group vs 141 mm Hg in the standard treatment arm. 11 Finally, the delay between baseline NCCT and start of BP treatment and ICH expansion may have occurred in this time frame, especially in patients at high risk of ICH expansion (early presenters with a spot sign).
Conclusions
We report 2 major findings in this study. For the first time, to our knowledge, we have prospectively validated that a CTA spot sign is associated with hematoma expansion, but the diagnostic accuracy of this marker was lower compared with findings in previous single-center studies. Second, even in patients with a CTA spot sign (and thus a higher risk for expansion), we found no evidence that intensive BP reduction lowers the risk for expansion or improves outcome. Hematoma expansion was defined as an increase of 33% or more in the hematoma volume from baseline to 24 hours. ICH, intracerebral hemorrhage; GCS, Glasgow coma scale; IVH, intraventricular hemorrhage; mRS, modified Rankin scale; SBP, systolic blood pressure; NCCT, non-contrast CT; CTA, CT angiography Age -yr 63.9 ± 13.7 61.1 ± 10.6 61.7 ± 13.0 57.1 ± 14.0
Hematoma expansion was defined as an increase of 33% or more in the hematoma volume from baseline to 24 hours. ICH, intracerebral hemorrhage; GCS, Glasgow coma scale; IVH, intraventricular hemorrhage; mRS, modified Rankin scale; SBP, systolic blood pressure; NCCT, non-contrast CT; CTA, CT angiography e-table 2. Univariate Analysis with all CTA before randomization and spot sign definition 2 (n = 101). 
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